Cargando…
Opportunities for PET to deliver clinical benefit in cancer: breast cancer as a paradigm
The glucose analogue fluorodeoxyglucose (FDG) has demonstrated enhanced uptake in the majority of tumours as a result of increased uptake and fixation by phosphorylation. It is the most widely used radiotracer in positron emission tomography (PET), being used in >90% of scans, and is useful for d...
Autores principales: | Fleming, Ian N., Gilbert, Fiona J., Miles, Ken A., Cameron, David |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
e-Med
2010
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2904028/ https://www.ncbi.nlm.nih.gov/pubmed/20605761 http://dx.doi.org/10.1102/1470-7330.2010.0020 |
Ejemplares similares
-
FDG-PET and colon cancer
por: Miles, Ken
Publicado: (2015) -
New paradigms in cervical cancer prevention: opportunities and risks
por: Ronco, Guglielmo, et al.
Publicado: (2008) -
Recognising the benefits and harms of breast cancer screening: an opportunity to target improvement
por: O'Donoghue, C, et al.
Publicado: (2013) -
An Innovative Non-Linear Prediction Model for Clinical Benefit in Women with Newly Diagnosed Breast Cancer Using Baseline FDG-PET/CT and Clinical Data
por: Kudura, Ken, et al.
Publicado: (2023) -
PET Tracers for Clinical Imaging of Breast Cancer
por: Peñuelas, Iván, et al.
Publicado: (2012)